458 related articles for article (PubMed ID: 11735673)
1. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
Nuijten MJ; Engelfriet P; Duijn K; Bruijn G; Wierz D; Koopmanschap M
Pharmacoeconomics; 2001; 19(10):1051-64. PubMed ID: 11735673
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
3. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
Weycker D; Yu EB; Woolley JM; Oster G
Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
Spalding JR; Hay J
Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
[TBL] [Abstract][Full Text] [Related]
6. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
7. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.
Harley CR; Frytak JR; Tandon N
Am J Manag Care; 2003 Oct; 9(6 Suppl):S136-43. PubMed ID: 14577718
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
[TBL] [Abstract][Full Text] [Related]
10. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
11. Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France.
Fautrel B; Woronoff-Lemsi MC; Ethgen M; Fein E; Monnet P; Sibilia J; Wendling D
Joint Bone Spine; 2005 Dec; 72(6):550-6. PubMed ID: 15996504
[TBL] [Abstract][Full Text] [Related]
12. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
Kobelt G; Eberhardt K; Geborek P
Ann Rheum Dis; 2004 Jan; 63(1):4-10. PubMed ID: 14672883
[TBL] [Abstract][Full Text] [Related]
13. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
15. The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis.
Sørensen J; Andersen LS
Pharmacoeconomics; 2005; 23(3):289-98. PubMed ID: 15836009
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of TNF antagonists in routine clinical practice and costs].
Prokes M
Vnitr Lek; 2009 Jan; 55(1):45-53. PubMed ID: 19227955
[TBL] [Abstract][Full Text] [Related]
17. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
Doan QV; Chiou CF; Dubois RW
J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
[TBL] [Abstract][Full Text] [Related]
18. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis.
Harrison DJ; Huang X; Globe D
Am J Health Syst Pharm; 2010 Aug; 67(15):1281-7. PubMed ID: 20651319
[TBL] [Abstract][Full Text] [Related]
19. Economical impact associated with a biological therapy prioritization protocol in patients with rheumatoid arthritis in the Hospital of Sagunto.
Borrás-Blasco J; Casterá MD; Cortes X; Rosique-Robles JD; Abad FJ
Expert Opin Biol Ther; 2014 Nov; 14(11):1561-7. PubMed ID: 25303321
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
